Page last updated: 2024-12-11
phenylahistin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
phenylahistin: antineoplastic from Aspergillus ustus; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9798496 |
| CHEMBL ID | 319291 |
| SCHEMBL ID | 81222 |
| MeSH ID | M0305583 |
Synonyms (9)
| Synonym |
|---|
| (-)-phenylahistin |
| CHEMBL319291 |
| phenylahistin |
| SCHEMBL81222 |
| 200815-37-8 |
| (3s,6z)-3-benzyl-6-[[5-(2-methylbut-3-en-2-yl)-1h-imidazol-4-yl]methylidene]piperazine-2,5-dione |
| GWMHBVLPNWHWGW-CNYBTUBUSA-N |
| Q15425275 |
| DTXSID801336373 |
Research Excerpts
Overview
Phenylahistin is a fungal diketopiperazine derived from isoprenylated (Phe-DeltaHis) cyclodipeptide. It is a new cell cycle inhibitor produced by Aspergillus ustus.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Phenylahistin is a fungal diketopiperazine derived from isoprenylated (Phe-DeltaHis) cyclodipeptide. " | ( Metabolism of phenylahistin enantiomers by cytochromes P450: a possible explanation for their different cytotoxicity. Abadie, C; André, F; Aninat, C; Delaforge, M; Hamon, V; Hayashi, Y; Heyd, B; Perrin, L, 2008) | 2.15 |
| "Phenylahistin is a new cell cycle inhibitor produced by Aspergillus ustus. " | ( Antitumor activity of phenylahistin in vitro and in vivo. Hayashi, Y; Kanoh, K; Katada, J; Kohno, S; Muramatsu, M; Uno, I, 1999) | 2.06 |
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " (-)-Phenylahistin proved to be less toxic on P450-rich hepatocytes than on P450-deprived KB lines." | ( Metabolism of phenylahistin enantiomers by cytochromes P450: a possible explanation for their different cytotoxicity. Abadie, C; André, F; Aninat, C; Delaforge, M; Hamon, V; Hayashi, Y; Heyd, B; Perrin, L, 2008) | 1.22 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (8)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1587854 | Antiproliferative activity against human MCF cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. |
| AID1587851 | Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. |
| AID1587856 | Antiproliferative activity against mouse P388 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. |
| AID1587853 | Antiproliferative activity against human K562 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. |
| AID1587852 | Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. |
| AID1587855 | Antiproliferative activity against human WiDr cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. |
| AID628581 | Cytotoxicity against human HT-29 cells | 2011 | Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22 | Highlights of marine invertebrate-derived biosynthetic products: their biomedical potential and possible production by microbial associants. |
| AID1587850 | Antiproliferative activity against human A432 cells assessed as reduction in cell growth incubated for 48 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 17.47
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.47) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (27.27%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (72.73%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||